Pfizer warns shareholders against Tutanota’s mini-tender offer

Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms

Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program

A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices

Novo Nordisk weathers pricing pressure, bets big on oral Wegovy

Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates

Zydus launches world’s first biosimilar of Nivolumab in India, cutting costs by 75%